Global Information
회사소개 | 문의 | 위시리스트

대사 관련 각종 제휴 계약 : 계약 조건 및 합의 내용

Global Metabolic Partnering 2014-2019: Deal trends, players and financials

리서치사 Current Partnering, a division of Wildwood Ventures Limited
발행일 2019년 05월 상품 코드 250301
페이지 정보 영문 500+ Pages
가격
US $ 2,995 ₩ 3,598,000 PDF by E-mail (Single user license)
US $ 4,495 ₩ 5,400,000 PDF by E-mail (Multi user license - 2 to 5 Users)
US $ 8,995 ₩ 10,807,000 PDF by E-mail (Multi User Site License - 6+ Users)
US $ 14,995 ₩ 18,016,000 PDF by E-mail (Global license)


대사 관련 각종 제휴 계약 : 계약 조건 및 합의 내용 Global Metabolic Partnering 2014-2019: Deal trends, players and financials
발행일 : 2019년 05월 페이지 정보 : 영문 500+ Pages

2007년 이후의 대사(Metabolic) 관련 각종 제휴 계약에 대해 조사 분석하고, 최근 각종 계약 동향, 대규모 계약 및 대형 제약회사의 계약 개요, 계약 구분·개발 단계·기술 구분·적응증 구분별 디렉토리 등의 정보를 전해드립니다.

주요 요약

제1장 서론

제2장 대사 관련 각종 계약 동향

  • 서론
  • 과거 수년간 대사 관련 제휴
  • 대형 제약회사의 계약 활동
  • 대사 관련 사업에 적극적이지 않은 대형 제약회사
  • 대사 관련 제휴 : 계약 종류별
  • 대사 관련 제휴 : 산업 부문별
  • 대사 관련 제휴 : 개발 단계별
  • 대사 관련 제휴 : 기술 종류별
  • 평균 계약 기간

제3장 주요 계약

  • 서론
  • 주요 계약 : 거래액별
  • 대형 제약회사와 관계된 주요 계약

제4장 대형 제약회사의 계약

  • 서론
  • 대형 제약회사의 제휴 계약 이용법
  • 기업 개요

제5장 계약 디렉토리

  • 서론
  • 계약 종류별
    • 자산 구입
    • 양도
    • 대형 제약회사의 아웃라이선싱
    • 공동 개발
    • 공동 R&D
    • 공동 판매
    • 서비스 계약
    • 공동 프로모션
    • CRADA
    • 크로스 라이선싱
    • 개발
    • 유통
    • 주식 구입
    • 라이선싱
    • 소송
    • 대출
    • 제조
    • 마케팅
    • 재료 이전
    • 옵션
    • 프로모션
    • 연구
    • 로열티 자금
    • 타결 관련
    • 스핀아웃
    • 서브 라이선스
    • 공급
    • 기술 이전
    • 종료
  • 개발 단계별
    • 디스커버리
    • 제제
    • 단계 I
    • 단계 II
    • 단계 III
    • 전임상
    • 규제
    • 제제
  • 기술 종류별
    • 분석
    • 동물 모델
    • 어세이
    • 생물학적 화합물
    • 바이오마커
    • 바이오소재
    • 혈액제재
    • 세포 배양
    • 세포 치료
    • 임상 검사
    • 기기
    • 진단
    • 디스커버리 툴
    • DNA 프로브
    • 약물 전달
    • 실현 기술
    • 설비
    • 유전자 치료
    • 게노믹스
    • 이미징
    • 임플란트
    • 인비트로 모델
    • 마이크로어레이
    • 나노테크놀러지
    • 천연 제품
    • 올리고뉴클레오티드
    • 희귀의약품
    • 포장
    • 펩티드
    • 가공
    • 프로테오믹스
    • 방사성/화학요법
    • 재편성 DNA
    • 재생 의학
    • 연구 서비스
    • 연구용 소모품
    • RNA 치료
    • 스크리닝
    • 저분자
    • 줄기세포
    • 독성
    • 백신

제6장 대사 관련 계약 : 적응증별

  • 대사
  • 말단 비대증
  • 에디슨병
  • 간경변
  • 쿠싱 증후군
  • 당뇨병
  • 지방간
  • 담석
  • 성장슨르몬질환
  • 갑상선기능항진증
  • 성선기능저하증
  • 갑상선기능저하증
  • 페닐케톤뇨증
  • 간질환
  • 리소좀 축적증
  • 영양소 및 비타민
  • 저신장
  • 항이뇨 호르몬 부적합 분비 증후군(SIADH)
  • 갑상선질환

제7장 제휴 기회

  • 온라인 파트너링
  • 파트너링 이벤트
  • 관련 자료

부록

도표

KSM 12.09.18

이 페이지에 게재되어 있는 내용은 최신판과 약간 차이가 있을 수 있으므로 영문목차를 함께 참조하여 주시기 바랍니다. 기타 자세한 사항은 문의 바랍니다.

Global Metabolic Partnering 2014-2019: Deal trends, players and financials report provides comprehensive understanding and unprecedented access to the metabolic partnering deals and agreements entered into by the worlds leading healthcare companies

Description

Global Metabolic Partnering 2014 to 2019 provides the full collection of Metabolic disease deals signed between the world's pharmaceutical and biotechnology companies since 2014.

Trends in Metabolic partnering deals

Financial deal terms for headline, upfront and royalty by stage of development

Metabolic partnering agreement structure

Metabolic partnering contract documents

Top Metabolic deals by value

Most active Metabolic dealmakers

Most of the deals included within the report occur when a licensee obtains a right or an option right to license a licensor's product or technology. More often these days these deals tend to be multi-component including both a collaborative R&D and a commercialization of outcomes element.

The report takes readers through the comprehensive Metabolic disease deal trends, key players and top deal values allowing the understanding of how, why and under what terms companies are currently entering Metabolic deals.

The report presents financial deal terms values for Metabolic deals, where available listing by overall headline values, upfront payments, milestones and royalties enabling readers to analyse and benchmark the value of current deals.

The initial chapters of this report provide an orientation of Metabolic dealmaking trends.

Chapter 1 provides an introduction to the report.

Chapter 2 provides an overview of the trends in Metabolic dealmaking since 2014 covering trends by year, deal type, stage of development, technology type and therapeutic indication.

Chapter 3 includes an analysis of financial deal terms covering headline value, upfront payment, milestone payments and royalty rates.

Chapter 4 provides a review of the leading Metabolic deals since 2014. Deals are listed by headline value. The chapter includes the top 25 most active Metabolic dealmakers, together with a full listing of deals to which they are a party. Where the deal has an agreement contract published at the SEC a link provides online access to the contract.

Chapter 5 provides comprehensive access to Metabolic deals since 2014 where a deal contract is available, providing the user with direct access to contracts as filed with the SEC regulatory authorities. Each deal title links via Weblink to an online version of the deal record contract document, providing easy access to each contract document on demand.

Chapter 6 provides a comprehensive directory of all Metabolic partnering deals by specific Metabolic target announced since 2014. The chapter is organized by specific Metabolic therapeutic target. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

In addition, a comprehensive appendix is provided with each report of all Metabolic partnering deals signed and announced since 2014. The appendices are organized by company A-Z, stage of development at signing, deal type (collaborative R&D, co-promotion, licensing etc) and technology type. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

The report also includes numerous tables and figures that illustrate the trends and activities in Metabolic partnering and dealmaking since 2014.

In conclusion, this report provides everything a prospective dealmaker needs to know about partnering in the research, development and commercialization of Metabolic technologies and products.

Report scope

Global Metabolic Partnering 2014 to 2019 is intended to provide the reader with an in-depth understanding and access to Metabolic trends and structure of deals entered into by leading companies worldwide.

Global Metabolic Partnering 2014 to 2019 includes:

  • Trends in Metabolic dealmaking in the biopharma industry since 2014
  • Analysis of Metabolic deal structure
  • Access to headline, upfront, milestone and royalty data
  • Access to hundreds of Metabolic deal contract documents
  • Comprehensive access to over 750 Metabolic deal records
  • The leading Metabolic deals by value since 2014
  • Most active Metabolic dealmakers since 2014
  • The report includes deals for the following indications: Acromegaly, Addison's disease, Cirrhosis, Cushing's syndrome, Diabetes, Type 1, Type 2, Insipidus, Fatty liver, Gallstones, Goitre, Growth hormone disorders, Gynaecomastia, Inborn errors of metabolism, Phenylketonuria, Hyperaldosteronism, Hypercalcaemia, Hyperthyroidism, Hypocalcaemia, Hypogonadism, Hypopituitarism, Hypothyroidism, Liver disease, Nonalcoholic steatohepatitis (NASH), Lysosomal storage disorders, Nutrition and vitamins, Rickets, Pheochromocytoma, Primary bilary cirrhosis, Prolactinemia, Short stature, Syndrome of Inappropriate Antidiuretic Hormone (SIADH), Thyroid disease, plus other metabolic indications.

In Global Metabolic Partnering 2014 to 2019, available deals and contracts are listed by:

  • Headline value
  • Upfront payment value
  • Royalty rate value
  • Stage of development at signing
  • Deal component type
  • Technology type
  • Specific therapy indication
  • Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

The Global Metabolic Partnering 2014-2019 report provides comprehensive access to available deals and contract documents for over 1,000 metabolic deals. Analyzing actual contract agreements allows assessment of the following:

  • What are the precise rights granted or optioned?
  • What is actually granted by the agreement to the partner company?
  • What exclusivity is granted?
  • What is the payment structure for the deal?
  • How are the sales and payments audited?
  • What is the deal term?
  • How are the key terms of the agreement defined?
  • How are IPRs handled and owned?
  • Who is responsible for commercialization?
  • Who is responsible for development, supply, and manufacture?
  • How is confidentiality and publication managed?
  • How are disputes to be resolved?
  • Under what conditions can the deal be terminated?
  • What happens when there is a change of ownership?
  • What sublicensing and subcontracting provisions have been agreed?
  • Which boilerplate clauses does the company insist upon?
  • Which boilerplate clauses appear to differ from partner to partner or deal type to deal type?
  • Which jurisdiction does the company insist upon for agreement law?

Benefits

Global Metabolic Partnering 2014 to 2019 provides the reader with the following key benefits:

  • In-depth understanding of Metabolic deal trends since 2014
  • Access Metabolic deal headline, upfront, milestone and royalty data
  • Research hundreds of actual contracts between Metabolic partner companies
  • Comprehensive access to over 750 links to actual Metabolic deals entered into by the world's biopharma companies
  • Indepth review of Metabolic deals entered into by the top 25 most active dealmakers
  • Benchmark the key deal terms companies have agreed in previous deals
  • Identify key terms under which companies partner Metabolic opportunities
  • Uncover companies actively partnering Metabolic opportunities

Table of Contents

Executive Summary

Chapter 1 - Introduction

Chapter 2 - Trends in Metabolic dealmaking

  • 2.1. Introduction
  • 2.2. Metabolic partnering over the years
  • 2.3. Metabolic partnering by deal type
  • 2.4. Metabolic partnering by industry sector
  • 2.5. Metabolic partnering by stage of development
  • 2.6. Metabolic partnering by technology type
  • 2.7. Metabolic partnering by therapeutic indication

Chapter 3 -Financial deal terms for Metabolic partnering

  • 3.1. Introduction
  • 3.2. Disclosed financials terms for Metabolic partnering
  • 3.3. Metabolic partnering headline values
  • 3.4. Metabolic deal upfront payments
  • 3.5. Metabolic deal milestone payments
  • 3.6. Metabolic royalty rates

Chapter 4 - Leading Metabolic deals and dealmakers

  • 4.1. Introduction
  • 4.2. Most active in Metabolic partnering
  • 4.3. List of most active dealmakers in Metabolic
  • 4.4. Top Metabolic deals by value

Chapter 5 - Metabolic contract document directory

  • 5.1. Introduction
  • 5.2. Metabolic partnering deals where contract document available

Chapter 6 - Metabolic dealmaking by therapeutic target

  • 6.1. Introduction
  • 6.2. Deals by Metabolic therapeutic target

Appendices

  • Appendix 1 - Directory of Metabolic deals by company A-Z since 2014
  • Appendix 2 - Directory of Metabolic deals by deal type since 2014
  • Appendix 3 - Directory of Metabolic deals by stage of development since 2014
  • Appendix 4 - Directory of Metabolic deals by technology type since 2014
  • Further reading on dealmaking
  • Deal type definitions
  • About Wildwood Ventures
  • Current Partnering
  • Current Agreements
  • Recent report titles from CurrentPartnering

Table of figures

  • Figure 1: Metabolic partnering since 2014
  • Figure 2: Metabolic partnering by deal type since 2014
  • Figure 3: Metabolic partnering by industry sector since 2014
  • Figure 4: Metabolic partnering by stage of development since 2014
  • Figure 5: Metabolic partnering by technology type since 2014
  • Figure 6: Metabolic partnering by indication since 2014
  • Figure 7: Metabolic deals with a headline value
  • Figure 8: Metabolic deals with upfront payment values
  • Figure 9: Metabolic deals with milestone payment
  • Figure 10: Metabolic deals with royalty rates
  • Figure 11: Active Metabolic dealmaking activity sinc 2014
  • Figure 12: Top Metabolic deals by value since 2014
Back to Top
전화 문의
F A Q
 
BCC Research